World's Best Scientists 2026 revealed!
Giorgio V. Scagliotti

Giorgio V. Scagliotti

D-Index & Metrics

Medicine

D-Index
99
Citations
60372
World Ranking
8409
National Ranking
281

Giorgio V. Scagliotti publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Giorgio V. Scagliotti sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 661 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Giorgio V. Scagliotti D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Giorgio V. Scagliotti sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Giorgio V. Scagliotti is affiliated with the University of Turin in Italy and has contributed extensively to the field of medicine, with a particular focus on pulmonary and respiratory medicine, oncology, and cancer research. Their research covers a wide range of subfields including molecular biology and surgery.

Their main research topics include:

  • Lung Cancer Treatments and Mutations
  • Prostate Cancer Treatment and Research
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • PARP inhibition in cancer therapy
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment

Scagliotti has frequently published in a variety of scientific journals. The primary publication venues include:

  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Clinical Lung Cancer
  • Critical Reviews in Oncology/Hematology
  • Cancer Research

Some of the recent papers authored or co-authored by Scagliotti are:

  • "The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015" (2021), Journal of Thoracic Oncology
  • "Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer" (2021), Journal of Thoracic Oncology
  • "Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial" (2020), The Lancet Oncology
  • "IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy" (2020), Journal of Thoracic Oncology
  • "Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial" (2021), The Lancet Oncology

Collaborations play a significant role in Scagliotti's work with frequent co-authors including Paolo Bironzo, Silvia Novello, Luisella Righi, Francesco Passiglia, and Massimo Di Maïo.

Best Publications

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

    William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson

  • Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

    Giorgio Vittorio Scagliotti;Purvish Parikh;Joachim von Pawel;Bonne Biesma

  • Lung cancer: current therapies and new targeted treatments

    Fred R Hirsch;Giorgio V Scagliotti;James L Mulshine;Regina Kwon

  • Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Jean Pierre Pignon;Hélène Tribodet;Giorgio V. Scagliotti;Jean Yves Douillard

  • Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

    Roy S. Herbst;Giuseppe Giaccone;Joan H. Schiller;Ronald B. Natale

  • Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

    Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti

  • Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

    Giorgio V. Scagliotti;F. De Marinis;M. Rinaldi;L. Crinò

  • Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

    David H. Henry;Luis Costa;Francois Goldwasser;Vera Hirsh

  • The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

    Giorgio Scagliotti;Nasser Hanna;Frank V Fossella;Katherine Sugarman

  • Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non–Small-Cell Lung Cancer

    Giorgio V. Scagliotti;Roldano Fossati;Valter Torri;Lucio Crinò

  • The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015.

    Andrew G. Nicholson;Ming S. Tsao;Mary Beth Beasley;Alain C. Borczuk

  • Prevalence of adrenal incidentaloma in a contemporary computerized tomography series

    S. Bovio;A. Cataldi;G. Reimondo;P. Sperone

  • Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

    Christian Rolfo;Philip C. Mack;Giorgio V. Scagliotti;Paul Baas

  • Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

    Alice T Shaw;Tae Min Kim;Lucio Crinò;Cesare Gridelli

  • Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.

    Paolo Ceppi;Marco Volante;Silvia Saviozzi;Ida Rapa

  • Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

    Giorgio Scagliotti;Silvia Novello;Joachim von Pawel;Martin Reck

  • ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

    P. Ceppi;M. Volante;S. Novello;I. Rapa

  • Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project

    L. Crinò;Giorgio V. Scagliotti;S. Ricci;F. De Marinis

  • Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

    L Crino;G V Scagliotti;M Marangolo;F Figoli

  • Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study

    Paolo Maione;Francesco Perrone;Ciro Gallo;Luigi Manzione

Frequent Co-Authors

Silvia Novello
Silvia Novello University of Turin
Mauro Papotti
Mauro Papotti University of Turin
Rafael Rosell
Rafael Rosell Autonomous University of Barcelona
Alfredo Berruti
Alfredo Berruti University of Brescia
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Filippo De Marinis
Filippo De Marinis European Institute of Oncology
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Joachim von Pawel
Joachim von Pawel The University of Texas MD Anderson Cancer Center
Keunchil Park
Keunchil Park The University of Texas MD Anderson Cancer Center
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees is a flexible and cost-effective way for students to advance in the medical field. Many choose nursing as a starting point, with several accredited and accessible programs available throughout the USA. For those aiming to minimize expenses while gaining a high-level qualification, researching the cheapest dnp online program can provide an affordable pathway to leadership roles.

Registered Nurses (RNs) may consider transitioning to a Bachelor of Science in Nursing (BSN) for better career prospects. However, it's important to weigh the average cost of rn to bsn programs to ensure the investment fits your budget.

Non-nursing graduates interested in healthcare can take accelerated routes to qualify as nurses. For example, specific schools offer a non nursing bachelor's to msn online program, allowing career changers to fast-track their nursing education.

Additionally, individuals without a nursing background may find online bsn programs for non nurses that offer flexible coursework and admissions criteria, broadening access to the profession.

Best Scientists Citing Giorgio V. Scagliotti

Trending Scientists

Recently Published Articles